EZH2 and synovial sarcoma: Indeed, both pediatric and adult patients with refractory SS have been enrolled in phase I and II clinical trials testing the novel EZH2 inhibitor, tazemetostat (ClinicalTrials.gov Identifiers: NCT02601937, NCT02601950, and NCT02875548).